Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.79 |
| ▸ | KDR | P35968 | 12/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.57 |
| ▸ | FLT1 | P17948 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | FLT4 | P35916 | 2/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053845 | 1.00 | ENPP1 (0.79) | ENPP1KDRFGFR1FLT1EGFR | |
| SCHEMBL1011724 | 1.00 | ENPP1 (0.79) | ENPP1KDRFGFR1FLT1EGFR | |
| SCHEMBL4373681 | 0.96 | ENPP1 (0.73) | ENPP1KDRFGFR1FLT1EGFR | |
| SCHEMBL29478510 | 0.95 | ENPP1 (0.71) | ENPP1KDRFLT1EGFRGAK | |
| SCHEMBL163465 | 0.95 | ENPP1 (0.71) | ENPP1KDRFLT1EGFRGAK | |
| Hydrochloric Acid SCHEMBL8307436 | 0.94 | ENPP1 (0.69) | ENPP1KDRFLT1EGFRGAK | |
| SCHEMBL16760503 | 0.93 | ENPP1 (0.77) | ENPP1KDRFGFR1FLT1EGFR | |
| SCHEMBL1507495 | 0.90 | ENPP1 (0.64) | ENPP1KDRFGFR1FLT1EGFR | |
| SCHEMBL1507551 | 0.90 | ENPP1 (0.64) | ENPP1KDRFGFR1FLT1EGFR | |
| SCHEMBL28412498 | 0.89 | ENPP1 (0.63) | ENPP1KDRFGFR1FLT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| EP-4334305-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-110546147-B | Phenoxyquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2022236101-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-3615526-B1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-07-06 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999010349-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| EP-0880508-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | ENPP1 2745/4885KDR 3921/4885FGFR1 2548/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ENPP1 1726/4885KDR 33/4885FGFR1 17/4885 |
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | KIT, ABL1, RB1 | ENPP1 3502/4885KDR 30/4885FGFR1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.